T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PPBI
526
DELISTED
Pacific Premier Bancorp
PPBI
| $226M | 0.02% |
5,647,159
-70,109
| -1% | -$2.91M |
|
|
NIMC
527
DELISTED
NiSource Inc. Series A Corporate Units
NIMC
| $225M | 0.02% |
2,015,586
-195,408
| -9% | -$21M |
|
528
Kymera Therapeutics
KYMR
$9.41B
| $225M | 0.02% |
3,550,528
+317,331
| +10% | +$18.5M |
|
|
ETRN
529
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
| $224M | 0.02% |
21,697,668
-432,535
| -2% | -$4.48M |
|
530
Vistra
VST
$49B
| $223M | 0.02% |
9,783,248
-8,020,455
| -45% | -$161M |
|
531
Monro
MNRO
$372M
| $222M | 0.02% |
3,814,040
+186,330
| +5% | +$11M |
|
532
Scholastic
SCHL
$786M
| $221M | 0.02% |
5,542,917
-12,229
| -0.2% | -$461K |
|
533
Acadia Pharmaceuticals
ACAD
$5.06B
| $221M | 0.02% |
9,486,261
+53,717
| +0.6% | +$1.08M |
|
534
American Water Works
AWK
$27.1B
| $220M | 0.02% |
1,162,907
-42,297
| -4% | -$7.39M |
|
535
Colgate-Palmolive
CL
$74.5B
| $219M | 0.02% |
2,566,549
-662,526
| -21% | -$51.7M |
|
536
Planet Fitness
PLNT
$3.7B
| $218M | 0.02% |
2,406,288
+311,450
| +15% | +$26.6M |
|
|
JBGS
537
JBG SMITH
JBGS
$695M
| $217M | 0.02% |
7,555,578
-367,768
| -5% | -$10.8M |
|
538
FB Financial Corp
FBK
$3.12B
| $217M | 0.02% |
4,948,973
-92,875
| -2% | -$4.16M |
|
539
Mettler-Toledo International
MTD
$28.8B
| $215M | 0.02% |
126,962
+501
| +0.4% | +$757K |
|
540
Liberty Broadband Class C
LBRDK
$5.18B
| $214M | 0.02% |
1,331,210
-3,418,707
| -72% | -$562M |
|
541
Oracle
ORCL
$455B
| $213M | 0.02% |
2,438,355
-149,640
| -6% | -$14M |
|
|
PARA
542
DELISTED
Paramount Global Class B
PARA
| $213M | 0.02% |
7,042,466
+4,626,691
| +192% | +$159M |
|
543
Westamerica Bancorp
WABC
$1.39B
| $210M | 0.02% |
3,643,235
+4,670
| +0.1% | +$263K |
|
544
Bristol-Myers Squibb
BMY
$131B
| $209M | 0.02% |
3,358,004
-541,195
| -14% | -$31.7M |
|
545
Denali Therapeutics
DNLI
$4.04B
| $207M | 0.02% |
4,635,433
-122,532
| -3% | -$5.81M |
|
546
Cactus
WHD
$5.77B
| $207M | 0.02% |
5,416,577
-266,970
| -5% | -$10.7M |
|
547
Harmonic Inc
HLIT
$1.53B
| $206M | 0.02% |
17,537,359
-207,679
| -1% | -$2.14M |
|
548
Nomad Foods
NOMD
$1.64B
| $205M | 0.02% |
8,087,884
+730,236
| +10% | +$18.8M |
|
549
St. Joe Company
JOE
$3.91B
| $205M | 0.02% |
3,939,083
-34,812
| -0.9% | -$1.69M |
|
550
Mine Safety
MSA
$7.37B
| $204M | 0.02% |
1,352,407
-34,146
| -2% | -$5.12M |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.